NCT07349472RecruitingPhase 2
Pentoxifylline in Patients With Ulcerative Colitis
Clinical Study Evaluating Safety and Efficacy of Pentoxifylline in Patients With Ulcerative Colitis
Source: ClinicalTrials.gov · Last updated 15 Apr 2026
Brief summary (registry, in English)
Ulcerative colitis (UC) is a persistent, idiopathic form of inflammatory bowel disease (IBD) marked by uninterrupted inflammation of the colon's mucosal lining, usually starting at the rectum and progressing proximally in a continuous manner. It manifests clinically with recurrent episodes of abdominal pain, bloody diarrhea, urgency, tenesmus, and weight loss. The precise cause of UC is still unknown; however, it is thought to arise from a multifactorial interaction involving genetic susceptibility, immune system dysregulation, disturbances in gut microbiota composition, and various environmental factors.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 9 Jan 2026
- Start date
- Jan 2026
- Primary completion date
- Jan 2027
- Lead sponsor
- Ihab Elsayed Hassan
- Diseases
- Ulcerative colitis
- NCT number
- NCT07349472
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 60
- From Jan 2026 to the primary completion date, Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients taking rectal or systemic steroids
- Patients taking immunosuppressives or biological therapies
- Addiction to alcohol and / or drugs
Other illness
- Colorectal cancer patients
- Known allergy to the studied medications
Other
- Breast feeding
- Significant liver and kidney function abnormalities
- Diabetic patients
- Patients with severe UC
Who the study is looking for
- Age ≥ 18 years
- Both male and female will be included
- Negative pregnancy test and effective contraception.
- Mild and moderate UC patients
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fayoum University Coordinator of this site? Confirm its status | Al Fayyum | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.